CD274 and neoplasm: Of note, the tumor of the patient with NE histology who completed 13 months of protocol therapy with ongoing benefit from durvalumab monotherapy had the highest TMB (13.2 mutations/Mb), but was microsatellite stable and PD‐L1 negative (Figure 3).